AIA Group Ltd Acquires 35,180 Shares of Abbott Laboratories $ABT

AIA Group Ltd raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 51.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 103,474 shares of the healthcare product maker’s stock after purchasing an additional 35,180 shares during the quarter. AIA Group Ltd’s holdings in Abbott Laboratories were worth $13,859,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in ABT. Charles Schwab Trust Co lifted its holdings in shares of Abbott Laboratories by 109.8% in the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after buying an additional 15,394 shares during the period. Asset Management One Co. Ltd. increased its stake in shares of Abbott Laboratories by 2.4% during the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after buying an additional 19,966 shares during the period. Nordea Investment Management AB raised its holdings in shares of Abbott Laboratories by 6.1% in the third quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after acquiring an additional 18,974 shares in the last quarter. AE Wealth Management LLC lifted its stake in Abbott Laboratories by 20.8% in the third quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after acquiring an additional 11,264 shares during the period. Finally, Mawer Investment Management Ltd. grew its holdings in Abbott Laboratories by 5.9% during the 3rd quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock worth $168,199,000 after acquiring an additional 70,122 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insider Activity

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 over the last quarter. Insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ABT shares. Daiwa Securities Group reduced their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Sanford C. Bernstein cut their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Barclays reduced their price objective on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Piper Sandler lowered their target price on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Finally, Argus cut their price target on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Stock Down 2.1%

Abbott Laboratories stock opened at $108.41 on Thursday. The business’s 50-day simple moving average is $113.54 and its two-hundred day simple moving average is $123.39. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The company has a market cap of $188.81 billion, a PE ratio of 29.14, a PEG ratio of 1.76 and a beta of 0.74. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the firm earned $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.